<DOC>
	<DOCNO>NCT02233023</DOCNO>
	<brief_summary>Study ass compare safety long term oral treatment Parkinson 's Disease pramipexole versus bromocriptine dopamine agonist , measure cross-sectional incidence ophthalmologic disturbance , especially sign retinal degeneration , match pair design</brief_summary>
	<brief_title>Ophthalmologic Safety Long Term Treatment With Pramipexole Compared Bromocriptine Other Dopamine Agonists Patients With Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<mesh_term>Bromocriptine</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agents</mesh_term>
	<criteria>Patients idiopathic Parkinson 's Disease Patients treat consecutively either pramipexole bromocriptine ( dopamine agonist except ropinirole ) least two half year ( i.e . 30 month ) . Interruptions ongoing dopamine agonist treatment le one month per year duration acceptable , however , interruption within last 6 month acceptable . Patients currently participate ongoing openlabel extension trial pramipexole may include meet requirement 30 month treatment Written inform consent accordance Good Clinical Practice ( GCP ) local legislation Patients treat less two half year ( i.e . 30 month ) actual dopamine agonist ( regardless duration treatment previous dopamine agonist ) Patient treat ropinirole Patients follow : Patients hereditary retinal disease and/or family history hereditary retinal disease Patients history druginduced retinopathy Patients history surgically lasertreated diabetic retinopathy Patients atypical parkinsonian syndrome due drug , metabolic disorder , encephalitis degenerative disease ( e.g . progressive , supranuclear palsy , multisystem atrophy ) Dementia disorder could impair sign informed consent Patients participate drug study receive investigational drug within 30 day prior first visit ( patient currently participate ongoing openlabel extension trial pramipexole may include meet requirement 30 month treatment duration</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>